FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Erik van Meegen

Research Profile

Chemicals & Drugs

Concepts & Ideas

Physiology

Procedures

Geographic Areas

Netherlands

Disorders

Occupations

Pharmacogenetics

Co-author Network

Publications

TOP 3
R M F van Schie; T I Verhoef; J A M Wessels; A M V Babajeff; Anthonius de Boer; Saskia Le Cessie; Anke Hilse Maitland-van der Zee; Frits R Rosendaal; Tom Schalekamp; Felix J M van der Meer; Erik van Meegen
An evaluation of gene-gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol.
Rianne M F van Schie; Talitha I Verhoef; Judith A M Wessels; Anthonius de Boer; Saskia Le Cessie; Anke Hilse Maitland-van der Zee; Frits R Rosendaal; Tom Schalekamp; Felix J M van der Meer; Erik van Meegen
Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data.
Tom Schalekamp; B P Brassé; Janine F M Roijers; Erik van Meegen; Felix J M van der Meer; E M van Wijk; Toine Egberts; Anthonius de Boer
VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Erik van Meegen (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: R M F van Schie; T I Verhoef; J A M Wessels; A M V Babajeff; Anthonius de Boer; Saskia Le Cessie; Anke Hilse Maitland-van der Zee; Frits R Rosendaal; Tom Schalekamp; Felix J M van der Meer; Erik van Meegen
An evaluation of gene-gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol.
Journal of thrombosis and haemostasis : JTH 2012;10(5):767-72.
2011: Rianne M F van Schie; Talitha I Verhoef; Judith A M Wessels; Anthonius de Boer; Saskia Le Cessie; Anke Hilse Maitland-van der Zee; Frits R Rosendaal; Tom Schalekamp; Felix J M van der Meer; Erik van Meegen
Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data.
European heart journal 2011;32(15):1909-17.
2007: Tom Schalekamp; B P Brassé; Janine F M Roijers; Erik van Meegen; Felix J M van der Meer; E M van Wijk; Toine Egberts; Anthonius de Boer
VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement.
Clinical pharmacology and therapeutics 2007;81(2):185-93.
2004: Tom Schalekamp; Mirjam Oosterhof; Erik van Meegen; Felix J M van der Meer; Jean Conemans; Mirjam Hermans; Irma Meijerman; Anthonius de Boer
Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status.
Clinical pharmacology and therapeutics 2004;76(5):409-17.
2003: Stephan D Fihn; Alain A P Gadisseur; Edwin Pasterkamp; Felix J M van der Meer; W G M Breukink-Engbers; Lya M Geven-Boere; Erik van Meegen; Hanneke de Vries-Goldschmeding; Irma Antheunissen-Anneveld; Annelies R van't Hoff; Derk Harderman; Margriet Smink; Frits R Rosendaal
Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus phenprocoumon.
Thrombosis and haemostasis 2003;90(2):260-6.
2002: Fernie J A Penning-van Beest; Encarnación B Gómez García; Felix J M van der Meer; Erik van Meegen; Frits R Rosendaal; Bruno H Ch Stricker
Levels of vitamin K-dependent procoagulant and anticoagulant proteins in over-anticoagulated patients.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2002;13(8):733-9.
2002: Fernie J A Penning-van Beest; Johanna M Geleijnse; Erik van Meegen; Cees Vermeer; Frits R Rosendaal; Bruno H Ch Stricker
Lifestyle and diet as risk factors for overanticoagulation.
Journal of clinical epidemiology 2002;55(4):411-7.
2001: Fernie J A Penning-van Beest; Erik van Meegen; Frits R Rosendaal; Bruno H Ch Stricker
Characteristics of anticoagulant therapy and comorbidity related to overanticoagulation.
Thrombosis and haemostasis 2001;86(2):569-74.
2001: Fernie J A Penning-van Beest; Erik van Meegen; Frits R Rosendaal; Bruno H Ch Stricker
Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs.
Clinical pharmacology and therapeutics 2001;69(6):451-7.
1999: Fernie J A Penning-van Beest; K K Aben; Erik van Meegen; R A de Man; J H Wilson; Bruno H Ch Stricker
Determination of serum liver tests during therapy with coumarin anticoagulants.
Journal of hepatology 1999;31(4):778-9.
1999: Fernie J A Penning-van Beest; Frits R Rosendaal; Diederick Grobbee; Erik van Meegen; Bruno H Ch Stricker
Course of the international Normalized Ratio in response to oral vitamin K1 in patients overanticoagulated with phenprocoumon.
British journal of haematology 1999;104(2):241-5.